Neuralink Is Now Available as a New Investment Opportunity at Moonshot

Imagine a world where people with disabilities can use the power of their minds to control computers without the need for any interface. It sounds like the plot of a science fiction movie, but it’s a reality that is already coming to life with Neuralink. The great news is that an investment in the company behind this reality is now available at Moonshot.

The concluding year has unmistakably underscored that the future is indelibly linked to innovative technologies, a belief fervently upheld by Moonshot. We remain steadfast in our commitment to furnish our investors with a spectrum of opportunities that transcends the mere pursuit of robust returns. Our endeavors are intricately woven into a narrative that not only aspires to yield financial gains but also significantly contributes to shaping a better tomorrow.

Why does Moonshot believe in Neuralink?

Founded by Elon Musk and a team of seven scientists and engineers in 2016, Neuralink is now one of the leading companies in the neurotech industry.

Over the years, Neuralink has created and enhanced a brain-computer interface called “Link,” a surgically embedded neural chip implant designed to decode and stimulate brain activity.

“In the long term, it is possible to restore full body motion.” — Elon Musk

The chip is about the size of a coin and can be embedded in a human skull and then transmitted to devices like a computer or a phone.

Structure of the Neuralink chip
Source: Neuralink

In addition to this, the company is also developing a robot that could install this chip in the skull and an app that would allow a person to manipulate a keyboard and mouse through brain signals.

Working on the Neuralink Robot
Source: Neuralink

Today, the company has made significant progress in testing aspects of its technology in animals, including a 2021 video showing a macaque playing a simple video game after implanting a chip in its brain. These results allowed the company to receive regulatory approval from the U.S. Food and Drug Administration (FDA) to proceed with the first human clinical trial of its experimental device.

This, in turn, represents an impressive milestone in the development of the technology, highlighting its potential to help people with disabilities regain movement and communication, as well as restore their vision.

Why is Neuralink worth investor attention?

Neuralink has now emerged as a company that can not only impact the neurological disease treatment field but also become an important part of investors' portfolios. Here are only a few of the numerous benefits that Neuralink investors get:

1. Massive market potential

The neurotech devices market value is expected to reach USD 35.5 billion by 2030. The application covers medical treatments for chronic disorders such as Parkinson’s and Alzheimer’s, restoring mobility, improving communication for non-verbal individuals, and treating neurological conditions. Neuralink provides a compelling entry point to this burgeoning sector.

2. Potential for future monetization

Beyond healthcare, Neuralink’s technology has broad applications in fields like artificial intelligence, augmented reality, and virtual reality. This investment offers potential access to various revenue streams, making it a forward-thinking, long-term choice.

3. Revolutionizing healthcare

Neuralink’s cutting-edge brain-computer interface technology has the potential to revolutionize healthcare by providing innovative solutions for neurological disorders and injuries. Investors can be part of a groundbreaking sector with the potential to save and enhance countless lives.

Neuralink, the company at the forefront of human-machine integration, is now available as a new investment opportunity on the Moonshot platform. Follow https://moonshot.ch/investment/neuralink/ to learn more and take advantage of this exciting opportunity.

Learn more